open access

Vol 80, No 2 (2012)
ORIGINAL PAPERS
Published online: 2012-02-27
Submitted: 2013-02-22
Get Citation

Measurement of bronchoconstrictive eicosanoids in chronic obstructive pulmonary disease

Iwona Gross-Sondej, Jerzy Soja, Krzysztof Sładek, Grażyna Pulka, Wojciech Skucha, Ewa Niżankowska-Mogilnicka
Pneumonol Alergol Pol 2012;80(2):120-126.

open access

Vol 80, No 2 (2012)
ORIGINAL PAPERS
Published online: 2012-02-27
Submitted: 2013-02-22

Abstract

Introduction: The aim of the study was the evaluation of the concentration of 9α11β prostaglandin F2 — a stable metabolite of prostaglandin D2 (PGD2) and leukotriene E4 (LTE4) in stable and exacerbated COPD patients.
Material and methods: 29 COPD patients aged 73 ± 8.34, mean FEV1 = 48.64 ± 15.75% of predictive value and 29 healthy controls aged 57.48 ± 10.86, mean FEV1 = 97.17 ± 13.81% of predictive value participated in this study. Samples of urine and blood were taken from COPD patients during exacerbation and in stable state of the disease; LTE4 was determined in urine using commercial enzyme immunoassay (EIA) and 9α11β prostaglandin F2 (9α11βPGF2) — stable metabolite of PGD2 was evaluated in blood and urine using GC/MS.
Results: LTE4 concentration in urine (677.15 vs. 436.4 pg/mg of creatinine; p = 0.035) and 9α11βPGF2 in blood serum (5.35 vs. 3.07 pg/ml; p = 0.007) were significantly higher in exacerbated COPD patients than in control group. There was no difference in LTE4 level in urine and 9α11βPGF2 in blood serum between exacerbated and stable COPD. The urinary 9α11βPGF2 concentration did not differ between all studied groups. We found a positive correlation between smoking history and the urine LTE4 level (r = 0.395; p = 0.002) as well as blood 9α11βPGF2 concentration (r = 0.603; p = 0.001) in COPD patients.
Conclusions: 9α11βPGF2 and LTE4 level in urine did not differ between the stable COPD group and the control group. We also did not find any difference between LTE4 level in urine and 9α11βPGF2 in blood and urine between exacerbated and stable COPD. Finally, LTE4 concentration in urine and 9α11βPGF2 in blood occurred to be significantly higher in exacerbated COPD patients than in control group.

Abstract

Introduction: The aim of the study was the evaluation of the concentration of 9α11β prostaglandin F2 — a stable metabolite of prostaglandin D2 (PGD2) and leukotriene E4 (LTE4) in stable and exacerbated COPD patients.
Material and methods: 29 COPD patients aged 73 ± 8.34, mean FEV1 = 48.64 ± 15.75% of predictive value and 29 healthy controls aged 57.48 ± 10.86, mean FEV1 = 97.17 ± 13.81% of predictive value participated in this study. Samples of urine and blood were taken from COPD patients during exacerbation and in stable state of the disease; LTE4 was determined in urine using commercial enzyme immunoassay (EIA) and 9α11β prostaglandin F2 (9α11βPGF2) — stable metabolite of PGD2 was evaluated in blood and urine using GC/MS.
Results: LTE4 concentration in urine (677.15 vs. 436.4 pg/mg of creatinine; p = 0.035) and 9α11βPGF2 in blood serum (5.35 vs. 3.07 pg/ml; p = 0.007) were significantly higher in exacerbated COPD patients than in control group. There was no difference in LTE4 level in urine and 9α11βPGF2 in blood serum between exacerbated and stable COPD. The urinary 9α11βPGF2 concentration did not differ between all studied groups. We found a positive correlation between smoking history and the urine LTE4 level (r = 0.395; p = 0.002) as well as blood 9α11βPGF2 concentration (r = 0.603; p = 0.001) in COPD patients.
Conclusions: 9α11βPGF2 and LTE4 level in urine did not differ between the stable COPD group and the control group. We also did not find any difference between LTE4 level in urine and 9α11βPGF2 in blood and urine between exacerbated and stable COPD. Finally, LTE4 concentration in urine and 9α11βPGF2 in blood occurred to be significantly higher in exacerbated COPD patients than in control group.
Get Citation

Keywords

COPD; LTE4; PGD2; bronchoconstrictive eicosanoids

About this article
Title

Measurement of bronchoconstrictive eicosanoids in chronic obstructive pulmonary disease

Journal

Advances in Respiratory Medicine

Issue

Vol 80, No 2 (2012)

Pages

120-126

Published online

2012-02-27

Bibliographic record

Pneumonol Alergol Pol 2012;80(2):120-126.

Keywords

COPD
LTE4
PGD2
bronchoconstrictive eicosanoids

Authors

Iwona Gross-Sondej
Jerzy Soja
Krzysztof Sładek
Grażyna Pulka
Wojciech Skucha
Ewa Niżankowska-Mogilnicka

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl